Vornado Joint Venture Agrees To Sell Part of 666 Fifth Avenue to Uniqlo
By Emon Reiser
Vornado Realty Trust said its 52%-owned retail joint venture has agreed to sell some of its square footage at 666 Fifth Avenue in New York, where Japanese retailer Uniqlo operates its U.S. flagship store.
Uniqlo agreed to buy 17,295 square feet of its 90,732-square-foot store in a transaction valued at $350 million. Vornado's joint venture will continue to own the 23,832 square feet occupied by Abercrombie & Fitch and Tissot stores at the location.
Vornado said $340 million in net proceeds from the sale, expected to close by the first quarter of 2025, will be used to partially repay Vornado's $390 million of preferred equity on the property and pass-through leases between the office condominium owner and the retail joint venture will be terminated. Uniqlo has entered into a separate transaction with the office condominium owner for the remainder of the store.
Vornado announced the deal in tandem with its second-quarter results. The real estate investment trust reported a quarterly profit of $50.8 million on $450.3 million in revenue.
Write to Emon Reiser at emon.reiser@wsj.com
(END) Dow Jones Newswires
August 05, 2024 17:14 ET (21:14 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks